Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Adma Biologics Inc (NASDAQ: ADMA) closed at $17.41 down -1.75% from its previous closing price of $17.72. In other words, the price has decreased by -$1.75 from its previous closing price. On the day, 0.81 million shares were traded. ADMA stock price reached its highest trading level at $17.75 during the session, while it also had its lowest trading level at $17.2801.
Ratios:
For a deeper understanding of Adma Biologics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 46.63 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 50.93. For the most recent quarter (mrq), Quick Ratio is recorded 3.26 and its Current Ratio is at 7.09. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.48.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 22 ’24 when Tade Brad L. sold 15,000 shares for $21.15 per share. The transaction valued at 317,250 led to the insider holds 199,433 shares of the business.
Grossman Adam S sold 48,967 shares of ADMA for $1,033,204 on Nov 22 ’24. The President and CEO now owns 1,989,007 shares after completing the transaction at $21.10 per share. On Nov 22 ’24, another insider, Grossman Adam S, who serves as the Director and Officer of the company, bought 48,967 shares for $21.30 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 4115549952 and an Enterprise Value of 4137867520. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 63.01, and their Forward P/E ratio for the next fiscal year is 23.93. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.56 while its Price-to-Book (P/B) ratio in mrq is 17.75. Its current Enterprise Value per Revenue stands at 10.809 whereas that against EBITDA is 32.868.
Stock Price History:
Over the past 52 weeks, ADMA has reached a high of $23.64, while it has fallen to a 52-week low of $4.27. The 50-Day Moving Average of the stock is -7.73%, while the 200-Day Moving Average is calculated to be 27.09%.
Shares Statistics:
For the past three months, ADMA has traded an average of 3.84M shares per day and 2677560 over the past ten days. A total of 236.38M shares are outstanding, with a floating share count of 228.48M. Insiders hold about 3.35% of the company’s shares, while institutions hold 88.43% stake in the company. Shares short for ADMA as of 1732838400 were 12906077 with a Short Ratio of 3.17, compared to 1730332800 on 15198480. Therefore, it implies a Short% of Shares Outstanding of 12906077 and a Short% of Float of 5.6199998.
